CA2300910A1 - Phosphono-carboxylate compounds for treating amyloidosis - Google Patents
Phosphono-carboxylate compounds for treating amyloidosis Download PDFInfo
- Publication number
- CA2300910A1 CA2300910A1 CA002300910A CA2300910A CA2300910A1 CA 2300910 A1 CA2300910 A1 CA 2300910A1 CA 002300910 A CA002300910 A CA 002300910A CA 2300910 A CA2300910 A CA 2300910A CA 2300910 A1 CA2300910 A1 CA 2300910A1
- Authority
- CA
- Canada
- Prior art keywords
- phosphono
- carboxylate compounds
- modulated
- subject
- treating amyloidosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010002022 amyloidosis Diseases 0.000 title 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical class OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 title 1
- 230000003941 amyloidogenesis Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
- 210000002469 basement membrane Anatomy 0.000 abstract 1
- 150000007942 carboxylates Chemical group 0.000 abstract 1
- 239000000039 congener Substances 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4062—Esters of acids containing the structure -C(=X)-P(=X)(XR)2 or NC-P(=X)(XR)2, (X = O, S, Se)
- C07F9/4065—Esters of acids containing the structure -C(=X)-P(=X)(XR)2, (X = O, S, Se)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described.
Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.
Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/912,574 US5869469A (en) | 1997-08-18 | 1997-08-18 | Phosphonocarboxylate compounds for treating amyloidosis |
| US08/912,574 | 1997-08-18 | ||
| US7444598P | 1998-02-11 | 1998-02-11 | |
| US60/074,445 | 1998-02-11 | ||
| PCT/IB1998/000967 WO1999008685A1 (en) | 1997-08-18 | 1998-04-10 | Phosphono-carboxylate compounds for treating amyloidosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2300910A1 true CA2300910A1 (en) | 1999-02-25 |
| CA2300910C CA2300910C (en) | 2008-02-26 |
Family
ID=26755679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002300910A Expired - Fee Related CA2300910C (en) | 1997-08-18 | 1998-04-10 | Phosphono-carboxylate compounds for treating amyloidosis |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1014994A1 (en) |
| JP (1) | JP2001515039A (en) |
| CA (1) | CA2300910C (en) |
| IL (1) | IL134619A0 (en) |
| NZ (1) | NZ550116A (en) |
| WO (1) | WO1999008685A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1054664B1 (en) * | 1998-02-11 | 2012-08-08 | BHI Limited Partnership | Method for modulating macrophage activation |
| MXPA00011213A (en) * | 1998-05-15 | 2003-04-22 | Neurochem Inc | Use of amyloid inhibitors for modulating neuronal cell death. |
| US6310073B1 (en) | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| JP4726304B2 (en) * | 1999-04-28 | 2011-07-20 | ベルス ヘルス （インターナショナル） リミティッド | Compositions and methods for treating amyloidosis |
| US6562836B1 (en) * | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
| PT1233770E (en) | 1999-12-03 | 2008-04-24 | Univ California At San Diego | Phosphonate compounds |
| JP2003532656A (en) * | 1999-12-23 | 2003-11-05 | ニューロケム インコーポレーティッド | Compounds and methods for modulating amyloid vasculopathy in the brain |
| US7414076B2 (en) | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| CN101128421A (en) | 2004-12-22 | 2008-02-20 | 神经化学（国际）有限公司 | Methods and compositions for treating amyloid-related diseases |
| AU2006342958A1 (en) | 2005-12-22 | 2007-11-08 | Bellus Health (International) Limited | Treatment of renal disorders, diabetic nephropathy and dyslipidemias |
| SG175603A1 (en) | 2006-10-12 | 2011-11-28 | Bellus Health International Ltd | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| CN105055432A (en) | 2008-01-25 | 2015-11-18 | 奇默里克斯公司 | Methods of treating viral infections |
| US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
| WO2011139709A2 (en) | 2010-04-26 | 2011-11-10 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
| EP4475846A1 (en) * | 2022-02-11 | 2024-12-18 | Tzerma LLC | Methods for preventing ectopic brain mineralization in alzheimer's disease and dementias |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1140049A (en) * | 1977-12-22 | 1983-01-25 | Dke J.E. Helgstran | Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid |
| DE3940410A1 (en) * | 1989-12-04 | 1991-06-06 | Schering Ag | NEW USE OF NMDA RECEPTOR ANTAGONISTS |
| CA2159326C (en) * | 1993-03-29 | 2000-05-30 | Robert Kisilevsky | Method for treating amyloidosis |
| AU6836394A (en) * | 1993-06-01 | 1994-12-20 | Cortex Pharmaceuticals, Inc. | Use of metabotropic receptor agonists in progressive neurodegenerative deseases |
| US6043283A (en) * | 1996-09-20 | 2000-03-28 | Baylor College Of Medicine | Tyramine compounds and their neuronal effects |
| CZ60499A3 (en) * | 1996-09-27 | 1999-08-11 | Guilford Pharmaceuticals Inc. | NAALADase-effecting agents, methods of treating glutamate abnormality, and methods of affecting neuronal activity in animals |
| SE9604582D0 (en) * | 1996-12-13 | 1996-12-13 | Astra Ab | Novel compounds |
-
1998
- 1998-04-10 IL IL13461998A patent/IL134619A0/en unknown
- 1998-04-10 EP EP98966963A patent/EP1014994A1/en not_active Ceased
- 1998-04-10 JP JP2000509424A patent/JP2001515039A/en not_active Withdrawn
- 1998-04-10 NZ NZ550116A patent/NZ550116A/en unknown
- 1998-04-10 WO PCT/IB1998/000967 patent/WO1999008685A1/en not_active Application Discontinuation
- 1998-04-10 CA CA002300910A patent/CA2300910C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001515039A (en) | 2001-09-18 |
| EP1014994A1 (en) | 2000-07-05 |
| CA2300910C (en) | 2008-02-26 |
| IL134619A0 (en) | 2001-04-30 |
| WO1999008685A1 (en) | 1999-02-25 |
| NZ550116A (en) | 2008-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2300910A1 (en) | Phosphono-carboxylate compounds for treating amyloidosis | |
| CA2159326A1 (en) | Method for Treating Amyloidosis | |
| EP1614432A3 (en) | Method for treating amyloidosis | |
| CA2356310A1 (en) | External preparations containing a basic drug | |
| CA2301017A1 (en) | Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds | |
| TR199801180T2 (en) | New compounds with analgesic effect. | |
| HUP0100437A2 (en) | Therapeutic formulation for administering tolterodine with controlled release | |
| CA2213411A1 (en) | Reduction of hair growth | |
| CA2310585A1 (en) | Novel administration form comprising an acid-labile active compound | |
| CA2370030A1 (en) | Sodium channel blocker compositions and the use thereof | |
| CA2180535A1 (en) | A method for treatment of psoriasis, by omeprazole or related compounds | |
| AU6801496A (en) | Film for the treatment of soils by fumigation | |
| AU8631891A (en) | Isoxazole compound, pharmaceutically acceptable salt thereof, and medicinal use thereof | |
| WO1999033450A3 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| AU3176695A (en) | Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid | |
| AU5623398A (en) | Methods of therapeutic administration of anti-cd40l compounds | |
| NO983864L (en) | Morphine and diamorphine salts of anionic, non-narcotic analgesics of the substituted carboxyl type | |
| NO890155L (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE INDOLPIPERIDIN COMPOUNDS. | |
| NO892820D0 (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE AMIDINO AND GUANIDINO DERIVATIVES. | |
| ZA979268B (en) | L-tartaric acid salt of a(1r) diastereomer of a 2-azadihy-droxybicyclo [2.2.1]heptane compound and the preparation of 2-azabicyclo[2.2.1] heptane compounds | |
| CA2279184A1 (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
| NO167861C (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF A NEW THERAPEUTIC ACTIVE INDOLOKINOL COMPOUND. | |
| AU4976599A (en) | Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives | |
| CA2289017A1 (en) | The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer | |
| AU2066897A (en) | Manufacture of liposomes and lipid-protein complexes by ethanolic injection and thin film evaporation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |